Karyopharm Reports Second Quarter 2015 Financial Results and Highlights Recent Progress
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Karyopharm (KPTI) Sell-Off Overdone, Leerink Partners Says
August 11, 2015 7:58 AM EDTLeerink Partners analyst Michael Schmidt reiterated an Outperform rating but lowered his price target on Karyopharm Therapeutics (NASDAQ: KPTI) to $41.00 (from $58.00) following yesterday's sell-off. The analyst said the move is overdone in their view.
Schmidt commented, "KPTI reported 2Q15 financial results and provided a pipeline update. Mgmt announced it... More
Karyopharm Therapeutics (KPTI) Misses Q2 EPS by 15c
August 10, 2015 7:41 AM EDTKaryopharm Therapeutics (NASDAQ: KPTI) reported Q2 EPS of ($0.92), $0.15 worse than the analyst estimate of ($0.77). Revenue for the quarter came in at $150 thousand versus the consensus estimate of $90 thousand.
Financial Outlook
Based on current operating plans, Karyopharm expects that its existing... More
